The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
 
Umberto Vitolo
Consulting or Advisory Role - Bayer; Constellation Pharmaceuticals; Genmab; Gilead Sciences; Incyte; Regeneron
Speakers' Bureau - Abbvie; Gilead Sciences; Incyte; Janssen Oncology; SERVIER
Research Funding - Morphosys (Inst)
Travel, Accommodations, Expenses - Abbvie; Incyte
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Bantam Pharmaceutical; Celgene (Inst); Debiopharm Group; Genentech (Inst); Karyopharm Therapeutics; Kite/Gilead; kymera; MorphoSys (Inst); Ryvu Therapeutics; Selvita; TG Therapeutics
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
John M. Burke
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; AstraZeneca; Bayer; BeiGene; Bristol Myers Squibb; Epizyme; Genentech/Roche; Kura Oncology; Kymera; Lilly; MorphoSys; Novartis; Seagen; TG Therapeutics; Verastem
Speakers' Bureau - Beigene; Seagen
 
Christopher P. Fox
Consulting or Advisory Role - Abbvie; AstraZeneca; Atara Biotherapeutics; Celgene/Bristol-Myers Squibb; Genmab; Kite/Gilead; MorphoSys; Ono Pharmaceutical; Orion; Roche
Speakers' Bureau - Gilead Sciences; Incyte; Janssen; Roche; Takeda
Research Funding - BeiGene
 
Marek Trneny
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; MorphoSys; Novartis; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Incyte; Janssen; MorphoSys; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Gilead Sciences; janssen; Roche; Takeda
 
Annalisa Chiappella
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Clinigen Group; Janssen-Cilag; Kite/Gilead; Roche; Secura Bio
Other Relationship - AstraZeneca; Celgene/Bristol-Myers Squibb; Clinigen Group; Incyte; Janssen-Cilag; Kite/Gilead; Novartis; Roche; Secura Bio
 
Maeve Waldron-Lynch
Employment - MorphoSys; Novartis (I)
Stock and Other Ownership Interests - MorphoSys; Novartis (I)
 
Nira Hadar
Employment - MorphoSys
Stock and Other Ownership Interests - Morphosys
 
Alok Pachori
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Georg Lenz
Honoraria - Abbvie; ADC Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Genmab/Seattle Genetics; Gilead Sciences; Incyte; Janssen-Cilag; MorphoSys; Novartis; Roche/Genentech
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Genmab/Seattle Genetics; Gilead Sciences; Incyte; Janssen-Cilag; MorphoSys; Novartis; Roche/Genentech
Research Funding - AGIOS; Aquinox; AstraZeneca; Bayer; Gilead Sciences; Janssen-Cilag; MorphoSys; Roche/Genentech; Verastem
Expert Testimony - MorphoSys; Roche
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Janssen-Cilag; Roche/Genentech